Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$23 Mln
P/E Ratio
--
P/B Ratio
1.07
Industry P/E
--
Debt to Equity
0.07
ROE
-1.12 %
ROCE
-99.47 %
Div. Yield
0 %
Book Value
2.43
EPS
-1.77
CFO
$-52.54 Mln
EBITDA
$-64.66 Mln
Net Profit
$-71.33 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Longeveron LLC (LGVN)
| 1.16 | -5.91 | 4.17 | 1.74 | -75.81 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Longeveron LLC (LGVN)
| -87.06 | -57.76 | -73.32 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell... formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida. Address: Life Science & Technology Park, Miami, FL, United States, 33136 Read more
Co-Founder, Chief Science Officer & Chairman
Dr. Joshua Michael Hare FACC, M.D.
Co-Founder, Chief Science Officer & Chairman
Dr. Joshua Michael Hare FACC, M.D.
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Longeveron LLC (LGVN) stood at $ 26 Mln as on 31-Dec-24
The share price of Longeveron LLC (LGVN) is $1.75 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Longeveron LLC (LGVN) has given a return of -75.81% in the last 3 years.
Longeveron LLC (LGVN) has a market capitalisation of $ 23 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Longeveron LLC (LGVN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Longeveron LLC (LGVN) and enter the required number of quantities and click on buy to purchase the shares of Longeveron LLC (LGVN).
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida. Address: Life Science & Technology Park, Miami, FL, United States, 33136
The CEO & director of Dr. Joshua Michael Hare FACC, M.D.. is Longeveron LLC (LGVN), and CFO & Sr. VP is Dr. Joshua Michael Hare FACC, M.D..
There is no promoter pledging in Longeveron LLC (LGVN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Longeveron LLC (LGVN) | Ratios |
|---|---|
|
Return on equity(%)
|
-111.59
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-667.77
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Longeveron LLC (LGVN) was $0 Mln.
$0.12
(
